Introduction
Tuberculosis (TB) is a disease that has been known for thousands of years, but is still one of the most serious global public health problems. According to estimates by the World Health Organization (WHO), in 2015 there were 10.4 million cases of active tuberculosis and 1.4 million deaths, making TB the leading global cause of death from a single infectious agent. In addition, drug resistance has recently emerged as a major concern in dealing with TB 1 .
TB can be classified as drug resistant (DR-TB) if it includes one of the following resistance patterns to anti-TB drugs: monoresistance (resistance to one first-line anti-TB drug only), polyresistance (resistance to two or more of these drugs, except for both rifampicin and isoniazid), multi-resistance (resistance to at least both rifampicin and isoniazid), and extensive resistance (resistance to both rifampicin and isoniazid, a fluoroquinolone, and at least one of three second-line injectable drugs) 2 .
Multidrug-resistant tuberculosis (MDR-TB) showed an estimated 480,000 new cases and 250,000 deaths in the world, while extensively resistant tuberculosis (XDR-TB) was reported in 117 countries in 2015 1 . The number of cases of drug-resistant tuberculosis has increased in Brazil, and 1,027 cases were reported in the country in 2015 3 .
As with drug-susceptible TB, loss to follow-up is one of the main problems in the treatment of DR-TB. Various factors are associated with loss to follow-up, such as drug toxicity, long duration of treatment, and other social determinants 4 . In a study on MRD-TB in South Africa in 2006, Holtz et al. 5 highlighted the lack of patient-provider interaction, drug use, and socioeconomic characteristics as the most significant factors associated with loss to follow-up.
Although TB treatment is free and highly efficacious in achieving cure, numerous cases still end in death 1 . In Brazil, considering new cases of MDR-TB, 10 .6% of cases died in 2012 2 . In a study in Bulgaria, Milanov et al. 6 found that weight loss or absence of weight gain and positive sputum smear at the start of treatment were factors associated with death of patients with drug-resistant TB. ChungDelgado et al. 7 reported that low schooling, previous episodes of TB, history of diabetes, and HIV infection were associated with death among cases of drug-resistant TB in Peru.
Considering the relative lack of studies analyzing drug-resistant TB in Brazil, this study aimed to investigate factors associated with loss to follow-up and death of cases in this type of TB in a tertiary reference center in the city of Rio de Janeiro, Brazil.
Methods
This was a retrospective cohort study of cases of DR-TB treated at the Professor Hélio Fraga Reference Center (CRPHF), Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation (ENSP/Fiocruz), Rio de Janeiro, Brazil, reported to the Information System on Special Treatments for Tuberculosis (SITETB) from January 1, 2012, to December 31, 2013.
CRPHF is a tertiary outpatient reference clinic under the Brazilian Unified National Health System (SUS) for diagnosis and treatment of cases of drug-resistant tuberculosis and non-TB mycobacterial infections. Most patients are referred from primary care services in the Greater Metropolitan Rio de Janeiro (Belford Roxo, Duque de Caxias, Itaguaí, Japeri, Mesquita, Nilópolis, Nova Iguaçu, Queimados, Seropédica, and São João de Meriti), besides individuals from other cities in the State of Rio de Janeiro (Centro-Sul Fluminense, Médio Paraíba, Baía de Ilha Grande, and part of the Mountainous Region -Petrópolis, Teresópolis, and Guapimirim).
SITETB is an online ancillary system of the SINAN (Information System on Diseases of Notification), dedicated to cases of drug-resistant tuberculosis and/or cases requiring special TB treatments (e.g., drug intolerance, toxicity, nephropathy, allergies), or cases of non-TB mycobacterial infections 2 . This system allows identifying the frequency and distribution of cases of DR-TB in the country, orienting management, drug supply, and epidemiological surveillance of cases.
The current study explored the following covariables: sex (male or female); age bracket (15-29 years, 30-49 years, and 50 or older); schooling (fewer than eight years, more than eight years, unknown); race/color (white, black, brown, Asian-descendant, unknown); clinical form (pulmonary, Cad. Saúde Pública 2018; 34(5):e00048217 extrapulmonary, mixed); year (2012 or 2013); resistance pattern (monoresistance, multi-resistance, polyresistance, extensive resistance); type of resistance (primary or acquired); type of entry (new case, reentry after loss to follow-up, treatment failure, relapse, resistance change, others); comorbidities (AIDS, diabetes, smoking, drug use, alcoholism). For the analysis of associated factors, the outcome variable (treatment success, treatment failure, loss to follow-up, death, others, and change of treatment regimen) was organized in three new categories, namely: "others", grouping the outcomes treatment success, treatment failure, regimen change, and others. The remaining outcomes were "loss to follow-up" and "death".
Definitions
According to WHO guidelines 8 , this study used the following terms with their respective definitions.
Cured is a case of pulmonary TB with a negative culture in the last month of treatment and on at least one previous occasion. Treatment completed is every case of TB that was completed without evidence of treatment failure, but without laboratory confirmation. Loss to follow-up is when a patient with TB did not initiate treatment or when treatment was interrupted for two consecutive months or more. Treatment failure is a TB case with a positive culture in the fifth month or later, in the course of treatment. Death is characterized when a TB patient dies for any reason in the course of treatment. Finally, treatment success is the sum of cured and treatment completed.
Statistical analysis
We analyzed the clinical and epidemiological characteristics of reported DR-TB cases in order to characterize the study population by means of frequency distributions, medians, and interquartile range for the quantitative variables. Differences in proportions between the groups were compared with the chi-square test (χ 2 ), or the Fisher's exact test when the expected frequency in the contingency tables was less than or equal to 5. For continuous variables, the Wilcoxon-Mann-Whitney non-parametric test was used. P-value < 0.05 was considered statistically significant. The measures of association were calculated using odds ratios (OR) with the respective 95% confidence intervals (95%CI).
Factors associated with loss to follow-up and death were analyzed with multinomial logistic regression. For this analysis, the outcome category "others" was used as the reference for the outcome response variable and compared to the other categories (others vs. loss to follow-up; and others vs. death). The covariables proposed in the multiple multinomial logistic regression models were selected from simple multinomial logistic regression based on analysis of significance via the Wald test, i.e., covariables that were significant in the Wald test (p-value < 0.20) were incorporated into the multiple multinomial logistic regression models. Multiple models were proposed to adjust for potential confounding and interaction, choosing the most adequate model that presented the lowest value for the Akaike information criterion (AIC), since it is a measure of the distance between the true model and the candidate models (Table 1) . Hosmer-Lemeshow test was used to verify the final multiple regression model's goodness of fit (HL = 5.792; GL = 12; p-value = 0.926). The measures of association were calculated using crude and adjusted OR with their 95%CI. Statistical analyses used the R software and nnet package, version 3.2.1 (R Development Core Team, Austria, Vienna; http://www.r-project.org).
The study was approved by the Ethics Research Commitee of the ENSP/Fiocruz, under case review CAAE: 55986316.7.0000.5240.
Results
From January 2012 to December 2013, a total of 257 patients were reported to the SITETB and initiated treatment for DR-TB at CRPHF. Of this total, 139 (54.1%) had treatment success as their outcome, 54 (21%) were lost to follow-up, 35 (13.6%) had treatment failure, and 21 (8.2%) died in the course of treatment. The majority of cases were males, with 179 (69.6%). Men showed higher percentages of loss to follow-up (n = 41; 22.9%) and death (n = 16; 8.9%) when compared to women. The most Cad. Saúde Pública 2018; 34(5):e00048217 Table 1 Proposed predictive models for loss to follow-up and death.
Models
Variables AIC heavily affected age bracket was 30-49 years (n = 135; 52.5%). The majority of cases had fewer than eight years of schooling (n = 149; 58%), and the most common skin color was brown among cases in treatment (n = 90; 35%) ( Table 2) . Multidrug-resistant cases (MDR-TB) were the most frequent (n = 178; 69.3%), and the great majority of cases in treatment showed acquired resistance (n = 224; 87.2%). New cases were the most frequent in the study population (n = 180; 70%). Loss to follow-up was higher among cases of reentry after loss to follow-up (n = 16; 59.3%), and death was also more frequent in cases of reentry after loss to follow-up (n = 5; 18.5%). The most frequent comorbidities among patients in treatment were smoking (n = 40; 15.6%), diabetes (n = 27; 10.5%), alcoholism (n = 25; 9.7%), drug use (n = 21; 8.17%), and AIDS (n = 12; 4.7%) ( Table 3) . Table 4 shows the logistic regression analysis for risk factors for loss to follow-up and death in DR-TB cases with the respective crude and adjusted odds ratios. Among the proposed models, the one with the lowest AIC for loss to follow-up and death was model 3 (AIC = 349.04) ( Table 1) . Among the factors associated with loss to follow-up in simple regression, age 50 years or older was a protective factor. Having fewer than eight years of schooling, reentering treatment after loss to follow-up, and drug use increased the odds of loss to follow-up. The statistically significant risk factors for death in simple regression were: reentry after loss to follow-up, treatment failure, polyresistance, and extensive resistance. Age 50 years or older was a protective factor against death (Table 4) .
In the multiple analysis, the age bracket covariable, with age 50 years or older as the reference category (OR = 0.11; 95%CI: 0.03-0.41), remained as a protective factor against loss to follow-up, aswas found in the simple analysis. The covariables fewer than eight years of schooling (OR = 2.71; 95%CI: 1.25-5.82) and reentry after loss to follow-up (OR = 6.50; 95%CI: 2.29-18.46) were associated with increased odds of loss to follow-up, as in the simple regression analysis. Meanwhile, drug use was no longer a significant predictor of loss to follow-up in the multiple regression model (Table 4) .
In the analysis of risk factors for death, reentry after loss to follow-up (OR = 9.36; 95%CI: 2.08-42.07) and treatment failure (OR = 5.01; 95%CI: 1.51-16.63) remained associated with death. However, after adjustment, resistance pattern was no longer a significant predictor of death (Table 4) .
Discussion
The main observations in this study were: (a) age 50 years or older is associated with lower risk of loss to follow-up and death in the course of treatment when compared to cases of 15-29 years of age, (b) reentry after loss to follow-up in previous treatment and fewer than eight years of schooling were associated with increased risk of loss to follow-up, and (c) reentry after loss to follow-up in previous treatment and treatment failure were independently associated with higher mortality in the course of treatment among cases of DR-TB.
Cad. Saúde Pública 2018; 34(5):e00048217 During the study period, 21% of cases were lost to follow-up of treatment for DR-TB. This percentage is similar to rates reported in some other countries such as Taiwan (29%) 9 , Uzbekistan (20%) 10 , and Argentina (20%) 11 . However, the rates are higher than in other countries, e.g., Lithuania (13%) 12 , Russia (12%) 13 , and Peru (10%) 14 . Our findings are not atypical, since a meta-analysis of more than nine thousand patients found 23% overall loss to follow-up 15 . These rates underscore the urgent need to better understand the factors associated with loss to follow-up in the treatment of DR-TB.
Our study found that patients with age 50 years or older had lower risk of loss to follow-up and death in the course of treatment for DR-TB. Garrido et al. 16 , analyzing factors associated with loss to follow-up of drug-susceptible cases of TB in Amazonas State, Brazil, also identified a lower risk of loss to follow-up in older patients. However, these results differ from another study, in which older patients had a 1.7 higher risk of loss to follow-up for treatment of DR-TB 10 .
According to our findings, DR-TB patients with less than eight years of schooling showed higher risk of loss to follow-up in the course of treatment. In various studies 17, 18, 19, 20 , education has been associated with better adherence to treatment of drug-susceptible, since it increases awareness of the disease. Importantly, education has also been acknowledged as an important proxy for economic status in Brazil 21 . Thus, low schooling is generally associated with a set of precarious socioeconomic conditions such as lack of resources, unhealthy living conditions, and overcrowded housing. Even with social and financial support, such conditions increase the vulnerability to tuberculosis and are directly associated with low adherence to treatment 16 .
We believe that any underlying association between poverty and loss to follow-up in this cohort could be attenuated by systematic efforts by programs to relieve the socioeconomic barriers to health care. Various descriptive and observational studies have shown that eliminating barriers in access to treatment or the supply of financial incentives can improve long-term adherence to treatment 22, 23, 24, 25 . Elucidating the ways throught with poverty jeopardizes the ability to complete the longterm TB treatment, socioeconomic support not with standing, will allow the interventions to facilitate treatment completion and consequently cure for poorer patients. The association between loss to follow-up and cases of reentry into treatment after loss to followup has been observed in other studies and highlights the importance of success in the first-line treatment regimen offered to the patient with DR-TB 10, 14 . According to a study by Lalor et al. 10 in Uzbekistan, the strongest individual risk factor for abandoning treatment of DR-TB was having interrupted a previous treatment.
A study in Peru found that patients who had interrupted previous treatment had an increased risk not only of abandoning the current regimen, but also of dying 15 . Previously treated patients should receive additional support at the start of a new regimen to emphasize the importance of adherence and conclusion of the process. Before starting a new treatment, cases of reentry after loss to follow-up require special attention to identify and address the issues that have contributed to the loss to followup and thus avoid serious outcomes, including death.
The association between failed treatment and death, as shown in our study, underscores the difficulties in the clinical management of these patients, since failure of previous treatment suggests that these patients have more resistant drugs in their treatment regimen. Thus, alternative and individualized treatment regimens should be considered, based on the results of drug-sensitivity tests in the regimen to decrease the odds of these patients evolving to death.
It is important to address the study's various limitations. The main one is the use of secondary data from health services, drawn from an information system focused on the clinical management of DR-TB cases in Brazil, where the available data are not standardized or originally intended for research. For example, we were unable to access the causes of death of patients in the course of treatment to better elucidate the factors leading to death in these patients. Another important limitation is that since this was a retrospective study, the data collected in the SITETB did not allow identifying and evaluating the reasons that led patients to interrupt or abandon treatment.
The reasons for loss to follow-up of patients with DR-TB should be known better for a proper understanding of the challenges involved in treatment adherence, especially in situations of DR-TB. We thus recommend qualitative studies to assess other factors that lead to increased risk of loss to follow-up and how they can be addressed directly with patients in order to avoid new losses to followup and even death. Despite these limitations, the study provides valuable information on factors associated with loss to follow-up and death in the course of treatment for DR-TB. Such information is available for use, could be used by TB control program managers to optimize the use of resources in the SUS.
Conclusion
Our findings point to some risk factors related to loss to follow-up and death, which are public health problems that contribute to worsening DR-TB. It is important for TB control programs and health professionals to identify risk factors in patients with increased risk of loss to follow-up and to adopt specific strategies to address this problem and prevent death. Various measures can be considered, such as the implementation and maintenance of financial benefits, development and strengthening of communication between health care providers, patients, and their families, and strengthening social support networks to help reduce the stigma faced by TB patients in their daily lives.
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